(HealthDay)—Use of pembrolizumab is supported among patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior receipt of a BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi) therapy, according to a study published online July 20 in JAMA Oncology.
- Classes
- Groups
- BLS Renewal
- ACLS Course Renewal
- PALS Renewal
- Skills Check
- Heartsaver® Courses
- Heartsaver® Pediatric First Aid CPR AED
- Heartsaver® Pediatric First Aid CPR AED Blended Learning
- Heartsaver® First Aid Instructor Led
- Heartsaver® First Aid Blended Learning
- Heartsaver® CPR AED Blended Learning
- Heartsaver® First Aid CPR AED Blended Learning
- Heartsaver® First Aid CPR AED Enrollment
- Heartsaver® CPR AED Enrollment
- Study
- Find My Ecard
- FAQ
- Shop
- Instructor Login